



Electroacupuncture for the Prevention of Postoperative Cognitive Dysfunction Among Older Adults Undergoing Hip and Knee Arthroplasty: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

OPEN ACCESS

Edited by:

Tzvi Dwolatzky, Technion Israel Institute of Technology, Israel

Reviewed by:

Haider Abdul-Lateef Mousa, University of Basrah, Iraq Liwei Wang, Xuzhou Central Hospital, China

*Correspondence:

Liang Ou 992254043@qq.com Yingfu Meng 56040939@qq.com

[†]These authors have contributed equally to this work

Specialty section:

This article was submitted to Geriatric Medicine, a section of the journal Frontiers in Medicine

Received: 16 September 2021 Accepted: 30 November 2021 Published: 04 January 2022

Citation:

Ou L, Shen Z, Zhang T, Chen Z, Zhang L, Xu D, Kong D, Qi Q, Huang Y, Huang W and Meng Y (2022) Electroacupuncture for the Prevention of Postoperative Cognitive Dysfunction Among Older Adults Undergoing Hip and Knee Arthroplasty: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Front. Med. 8:778474. doi: 10.3389/fmed.2021.778474 Liang Ou^{1*†}, Zhen Shen^{2†}, Tiantian Zhang³, Zehua Chen⁴, Lin Zhang¹, Daoqing Xu¹, Dezhong Kong¹, Qi Qi¹, Yanchang Huang¹, Weichen Huang¹ and Yingfu Meng^{1*}

¹ Department of Orthopedics, The Second Affiliated Hospital of Guizhou University of Chinese Medicine, Guiyang, China, ² Department of Orthopedics, Kunming Municipal Hospital of Traditional Chinese Medicine, The Third Affiliated Hospital of Yunnan University of Chinese Medicine, Kunming, China, ³ The Graduate School, Hunan University of Chinese Medicine, Changsha, China, ⁴ The Fifth Clinical Medical College of Guangzhou University of Chinese Medicine, Guangzhou, China

Background: Postoperative cognitive dysfunction (POCD) is a common surgical complication in elderly patients undergoing hip and knee replacement. Electroacupuncture (EA) may have a protective effect on postoperative cognitive function, but relevant evidence remains uncertain.

Objective: To systematically evaluate the evidence of EA for the prevention of POCD after total joint arthroplasty.

Methods: PubMed, Embase, Cochrane Central Register of Controlled Trials (CENTRAL), China National Knowledge Infrastructure (CNKI), Wanfang Data, VIP, and Chinese Biomedical Literature Database (CBM) databases were searched until May 1, 2021. Randomized controlled trials (RCTs) in which patients undergoing hip and knee replacement pretreated with EA for preventing POCD were included. The risk of bias was assessed by the Cochrane Collaboration tool. Meta-analysis was performed using Review Manager version 5.4.

Results: A total of 11 RCTs with 949 patients were identified. Meta-analysis showed that compared with controls, EA pretreatment significantly reduced the incidence of POCD at 1, 3, and 7 days and 3 and 6 months after the operation. EA was also superior in improving the Mini-Mental State Examination (MMSE) scores on the third postoperative day, but not on the first postoperative day. Neuron-specific enolase (NSE) and interleukin-1 β (IL-1 β) in the EA group were significantly lower than that in the control group. There was no difference in S100 β between the EA group and the control group. Compared to the control group, tumor necrosis factor- α (TNF- α) levels were not significantly lower in the EA group at postoperative hour 0, while significantly decreased at postoperative hours 24 and 48.

1

Conclusion: Our results suggest that EA pretreatment is an effective adjunctive therapy for reducing the incidence of POCD for patients receiving total joint replacement surgery. Its effect was embodied in improving the MMSE scores and NSE, IL-1 β , and TNF- α levels, whereas it had no significant effect on S100 β levels. Meanwhile, the benefits of EA for improving POCD need further strengthening and support from more large-scale, high-quality, and good-homogeneity RCTs.

Systematic Review Registration: https://osf.io/xb3e8.

Keywords: electroacupuncture, postoperative cognitive dysfunction, arthroplasty, prevention, elderly, metaanalysis, systematic review

INTRODUCTION

Postoperative cognitive dysfunction (POCD) is a common complication in elderly surgical patients, which seriously threatens early rehabilitation after surgery of patients and their long-term quality of life (1, 2). With the deepening of the aging of society, the number of older adults who are undergoing anesthesia and surgery is increasing, which will attribute to a high frequency of POCD. Meanwhile, additional diseases and poor basal functional status of elderly patients lead to an increased incidence of POCD (3). As previously reported, the prevalence of POCD ranged from 25 to 40% among elderly patients (4). POCD is a neurological dysfunction, characterized by the continuous decline of cognitive performance after surgical anesthesia, including disturbances in consciousness, orientation, thinking, memory, and executive function. Furthermore, studies have found that POCD could potentially result in an increased risk of some neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease (5-7). However, POCD remains difficult to treat effectively, due to the pathophysiology and risk factors that are incompletely understood (8).

Cognitive dysfunction following hip and knee joint replacement surgery has received a great deal of attention during the last few decades (9). Once a POCD occurs, it means that postoperative rehabilitation will be delayed and hospital stay will be prolonged for them. In more serious cases, POCD would directly or indirectly lead to surgery failure. Apparently, these consequences contradict the concept of enhanced recovery after surgery that aims to have the most favorable treatment course for the patient after surgery (10). Taking into consideration that no effective treatment for POCD has been currently developed, we should emphasize the importance of prevention strategies. In other words, elderly patients undergoing hip and knee joint replacement surgery could be treated with preoperative intervention to decrease the risk of POCD.

Electroacupuncture (EA) is an improvement method combining acupuncture and electric stimulation, which uses an electrical device connected to a needle to send electrical currents to the acupoint and, thereby, enhance the stimulation. When the acupuncture point has a sense of qi, the therapist selects the wave type, slowly adjusts to the required output current, and performs electrical stimulation generally for 5–20 min. Numerous studies have demonstrated the cognitive improvement effects of EA stimulation over the past several years (11, 12). EA applied before surgery can effectively reduce the dose of narcotic drugs, improve stress response, reduce the occurrence of postsurgical complications, and promote functional rehabilitation in patients undergoing surgery (13, 14). Thus, EA has been proposed to be used for the treatment of various kinds of neurological disorders, including POCD. Recently, there are a growing number of studies focusing on preventing and treating POCD with EA, especially for patients receiving joint replacement surgery. However, to the best of our knowledge, no meta-analysis has as yet evaluated the effects of EA for the prevention of POCD among older adults undergoing hip and knee arthroplasty. Consequently, this meta-analysis of randomized controlled trials (RCTs) was performed to summarize the available evidence to investigate the preventive therapeutic efficacy of EA on POCD for them.

METHODS

Ethical approval was not provided in this study because all the analyses were based on previously published studies. This study was registered in the Open Science Framework (https:// osf.io/XB3E8) and performed in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guideline (15).

Research Strategy

Potentially relevant studies were searched in PubMed, Embase, Cochrane Central Register of Controlled Trials (CENTRAL), China National Knowledge Infrastructure (CNKI), Wanfang Data, Chinese Scientific Journal Data (VIP), and Chinese Biomedical Literature Database (CBM), up to May 1, 2021. Search terms, such as "electroacupuncture," "arthroplasty," "joint replacement," "total knee arthroplasty (TKA)," "total hip arthroplasty (THA)," "postoperative cognitive dysfunction," "POCD," and "randomized controlled trial", were used to retrieve. Detailed search strategies are given in **Supplementary Figure 1**. Meanwhile, we added a manual search for references of included studies.

Eligibility Criteria

Randomized controlled trials related to using EA for the prevention of POCD after hip and knee replacement in elderly patients were included. The included studies should meet all of the following criteria: (1) Patients: patients (>60 years old) undergoing primary THA and TKA and without



cognitive dysfunction before intervention; (2) Intervention: EA; (3) Comparators: EA vs. blank control, EA vs. sham EA or placebo; (4) Outcomes: the incidence of POCD as the main evaluation index to be reported and secondary outcomes such as the Mini-Mental State Examination (MMSE) scores, neuronspecific enolase (NSE), S100 β , interleukin-1 β (IL-1 β), and tumor necrosis factor- α (TNF- α) to be reported selectively; and (5) Study design: a clinical randomized controlled study published in Chinese or English. Studies would be excluded if met any of the following criteria: observational studies, protocols, case reports, animal experimental studies, reviews, duplicated publications, and full-text unavailable articles.

Data Extraction

First, two reviewers (LO and TZ) independently went through the standard literature screening process: removing duplicate studies, eliminating obviously irrelevant studies by reading the titles and abstracts, and including eligibility studies by reading the full text.

Second, we used a standardized form to independently extract the main information from included articles including primary author, publication year, age and gender of patients, sample size, type of anesthesia, type of operation, intervention type, intervention parameters, and outcomes. Finally, disagreement in the above process, if any, would be resolved through discussion or consultation with the third reviewer (ZS).

Quality Assessment

Adhering to the standards advised by the Cochrane Collaboration risk of bias table (16), two investigators (LO and TZ) assessed the methodological quality of all the included pieces of literature independently. Any inconsistency was resolved by discussion with the third author (ZS). The risk of bias for each study was evaluated from the following seven aspects: random sequence generation, allocation concealment, blinding of participants and personnel, blinding of outcome assessment, the integrity of results data, selective reporting of results, and

TABLE 1 | Characteristics of the included randomized clinical trials.

References	Age (years)		ider (male/ female)		mple ize	Operation type	Type of anesthesia/anesthesia drugs			Intervention	Outcomes (time points for evaluation)
	EG	CG	EG	CG	EG	CG	_		EG	CG	Acupoints/stimulation parameter/time	
Li et al. (22)	77.2 ± 3.0	76.8 ± 2.7	16/26	14/28	42	42	THA	Spinal-epidural anesthesia/bupivacaine, lidocaine, midazolam	EA	Blank	MS1, MS5/continuous wave, 200 HZ/after anesthesia, through completion of surgery	Incidence of POCD (on 3 d, 7 d, 3 m), NSE (on 0 h, 24 h, 48 h), S-100 β (on 0 h, 24 h, 48 h), AE
Wang et al. (24)	>70	>70	NR	NR	40	40	THA	Spinal-epidural anesthesia/bupivacaine, lidocaine, midazolam	EA	Blank	MS1, MS5, MS7, MS10/continuous wave, 200 HZ/after anesthesia, through completion of surgery	Incidence of POCD (on 3 d, 7 d, 3 m), AE
Zhao et al. (18)	65.2 ± 4.0	66.7 ± 3.8	12/18	14/16	30	30	ТКА	General anesthesia/fentanyl, midazolam, propofol, cisatracurium besilate, remifentanil	EA	Sham EA	EX-HN1, DU24, DU20, GB13, Ll4, LR3/dilatational wave, 2/100 Hz, 3 mA/30 min, once daily, and 5 days consecutively prior to the surgery	$\begin{array}{l} \mbox{Incidence of POCD (on 1 d, 3 d)} \\ \mbox{MMSE (on 24 h, 72 h), S-100 β} \\ \mbox{(on 24 h, 72 h), IL-1 β (on 24 h, 72 h), TNF-α (on 24 h, 72 h), AE} \end{array}$
Jiang et al. (25)	70.2 ± 4.5	71.2 ± 4.8	21/22	20/25	43	45	THA/TKA	General anesthesia/midazolam, propofol, rocuronium bromide, sufentanil, remifentanil	EA	Blank	DU20, DUI4/2-15 Hz/30 min, once daily, and 5 days consecutively prior to the surgery	Incidence of POCD (on 1 d, 7 d)
Liu et al. (19)	65 ± 8	66 ± 5	25/35	26/34	60	60	THA	General anesthesia/fentanyl, midazolam, propofol, cisatracurium besilate	EA	Blank	Ll4, LR3/dilatational wave, 2/10 Hz/30 min, once daily, 3 days prior to the surgery and 3 days after surgery, and 30 min before anesthesia, through completion of surgery	Incidence of POCD (on 3 d), MMSE (on 72 h), IL-1 β (on 0 h, 24 h), TNF- α (on oh, 24 h)
Liu et al. (20)	66 ± 7	67 ± 6	16/24	17/23	40	40	THA	General anesthesia/fentanyl, midazolam, propofol, cisatracurium besilate, remifentanil	EA	Blank	Ll4, LR3/dilatational wave, 2/10 H2/30 min, once daily, 3 days prior to the surgery and 3 days after surgery, and 30 min before anesthesia, through completion of surgery	24 h, 48 h), S-100 β (on 0 h, 24
Xie et al. (23)	71.9 ± 7.2	70.8 ± 7.7	42/18	37/23	60	60	THA	General anesthesia/midazolam, propofol, fentanyl, cisatracurium besilate, sevoflurane, remifentanil	EA	Blank	GB13, DU24/continuous wave/30 min before completion of surgery, and 30 min, once daily, 2 days after surgery	7 d)
Xu et al. (17)	77.0 ± 6.3	78.4 ± 5.5	32/18	29/21	50	50	THA	General anesthesia/midazolam, remifentanil, propofol, rocuronium bromide, sufentanil	EA	Blank	Ll4, LR3/dilatational wave, 2/10 Hz/30 min before anesthesia, through completion of surgery	Incidence of POCD (on 1 d, 3 d 7 d), MMSE (on 24 h, 72 h)
Tao et al. (21)	72.5 ± 6.7	73.3 ± 5.90) 15/15	14/16	30	30	THA	General anesthesia/midazolam, sufentanil, cisatracurium besilate, propofol, sevoflurane	EA	Blank	DU20, PC6, DU24/dilatational wave, 2–15 Hz/after anesthesia, through completion of surgery	Incidence of POCD (on 1d, 7d)
Zhang et al. (27)	74.2 ± 5.9	75.0 ± 6.5	19/22	20/27	41	47	THA/TKA	General anesthesia/midazolam, sufentanil, vecuronium, propofol, isoflurane	EA	Blank	DU20, DU24/dilatational wave, 2–15 Hz/30 min before anesthesia, through completion of surgery	Incidence of POCD (on 1 d, 7 d S-100 β (on 0 h, 24 h), AE
Zhang et al. (26)	67.5 ± 4.7	70.1 ± 5.3	15/19	20/25	34	35	ТКА	General anesthesia/sufentanil, cisatracurium besilate, propofol, isoflurane	EA	Blank	DU20, DU24/dilatational wave, 2–15 Hz/30 min after anesthesia	Incidence of POCD (on 1 d, 7 d) S-100 β (on 0 h, 24 h), IL-1 β (or 0 h, 24 h), TNF- α (on 0 h, 24 h)

EG, electroacupuncture group; CG, control group; THA, total hip arthroplasty; TKA, total knee arthroplasty; POCD, postoperative cognitive dysfunction; AE, adverse event; NR, No record.



other biases. The assessment result of each item is classified into three categories: high, unclear, and low risk.

Statistical Analysis

The Review Manager version 5.4 software (2020) (Cochrane, UK) provided by the Cochrane Collaboration was used to conduct all the meta-analyses of the observation outcomes in the included studies, and the results were illustrated by the forest map intuitively. In this study, continuous variables were pooled by mean difference (MD) and dichotomous variables were pooled by odds ratio (OR). All the pooled effects were expressed with 95% CI. Heterogeneity was tested by Cochran's Q test and I^2 statistic. An I^2 statistic >50% represented high heterogeneity. Subsequently, subgroup analysis or sensitivity analysis would be applied to investigate the sources of heterogeneity, when there was substantially heterogeneous. The random-effects or fixedeffects models were selected depending on the heterogeneity. Publication bias was estimated by Begg's test and Egger's test, which are conducted by using the Stata 14 (2015) (StataCorp LP, College Station, TX, USA). Value of p < 0.05 was considered to be statistically significant.

RESULTS

Study Identification and Selection

A total of 1,013 related clinical trials were identified by the search strategy and imported into EndNote X8 to remove duplicate literature. After the removal of 306 repeated studies and excluding 684 studies through the title and abstract screening, leaving 26 full-text articles were reviewed and 15 of them were excluded. A total of 11 trials (17–27) met inclusion criteria and were selected for the analysis. The detailed selection flowchart is shown in **Figure 1**.

Characteristics of Included Trials

All the included trials were conducted in China, and 949 patients who were over 60 years old were enrolled. Of the included 11 clinical trials, 9 studies (17–21, 23, 25–27) were given the method of general anesthesia and 2 trials (22, 24) were carried out under spinal-epidural anesthesia. In terms of operation type, THA and

TKA were with 7 (17, 19–24) and 2 trials (18, 26), respectively. In addition, two trials (25, 27) combined the THA and TKA together for study. The vast majority of trials (n = 10) compared EA with blank and only one study (18) compared EA with sham EA. The stimulus frequency and duration of EA treatment differed among studies. The most commonly used acupoints were "Baihui" (DU20) and "Shenting" (DU24). Study characteristics are shown specifically in **Table 1**.

Risk of Bias

A total of seven trials (17, 19-22, 24, 25) were randomized in accordance with the random number table and one study (18) used a computer-generated random list. Two trials (26, 27) mentioned random without any method and the remaining one article (23) selected an incorrect randomization with the order of operation time. The allocation concealment processes used in studies were unclear, except that one study (18) used an opaque envelope to seal random numbers. Blind methods for participants were detailed reported in one study (18), which used sham EA as a control. Detection bias performed well in most of the included studies and the dropout rate was reported in four articles (18, 24-26). Because of the insufficient information provided, selective reporting could not be judged in all the studies. Other biases were assessed to be of low risk in all the included trials. An overview of the risk of bias assessment of the included studies is shown in Figure 2.

Meta-Analysis Incidence of POCD

The results from meta-analysis and the evidence quality of the effect of EA on POCD are given in **Table 2**. All the 11 included studies (17–27) reported the primary outcome. An overall meta-analysis showed moderate-certainty reduction in the incidence of POCD for EA pretreatment [OR = 0.40 (95% CI: 0.32, 0.49), p < 0.00001, $I^2 = 0\%$]. A further subgroup analysis was conducted to estimate the effects of EA on the incidence of POCD at 1, 3, 7 days, and 3 and 6 months after operation. For short-term outcomes, EA pretreatment significantly decreased the incidence of POCD at postoperative day 1 [OR = 0.43 (95% CI: 0.30, 0.45]).

TABLE 2 Main findings of the meta-analysis of electroacupuncture for the prevention of POCD after hip and knee arthroplasty.
--

Variable	No. of studies	No. of participants	Effect estimate (95% CI)	I ² Heteogeneity, %	GRADE
Incidence of POCD					Low
1 d	7	606	0.43 (0.30-0.62)	0	
3 d	7	644	0.43 (0.29-0.62)	0	
7 d	8	710	0.42 (0.26-0.69)	0	
3 m	2	164	0.27 (0.12-0.61)	0	
6 m	2	164	0.20 (0.07-0.57)	0	
Treatment $= 1$	6	1,410	0.38 (0.29–0.50)	0	Low
Treatment >1	5	1,096	0.41 (0.29-0.60)	0	
General anesthesia	9	1,850	0.46 (0.36-0.60)	0	Low
Spinal-epidural anesthesia	2	656	0.29 (0.19-0.50)	0	
MMSE scores					Moderate
1 d	2	160	1.77 (-1.13 to 4.67)	94	
3 d	4	360	2.21 (1.19–3.23)	84	
NSE					Very Low
0h	2	116	-0.35 (-0.69 to -0.02)	0	
24 h	2	116	-2.20 (-2.69 to -1.70)	0	
48 h	2	116	-1.23 (-1.68 to -0.77)	37	
S-100β					Very low
Oh	4	261	-0.08 (-0.18 to 0.02)	79	
24 h	5	321	-0.05 (-0.11 to 0.01)	59	
48 h	2	116	-0.15 (-0.36 to 0.07)	68	
72 h	2	140	-0.06 (-0.17 to 0.06)	64	
IL-1β					Very low
Oh	3	290	-1.72 (-3.28 to -0.16)	53	
24 h	4	350	-16.43 (-28.43 to -4.43)	99	
72 h	2	140	-31.99 (-46.04 to -17.94)	97	
TNF-α					Very low
Oh	3	290	-2.35 (-4.88 to 0.18)	81	
24 h	4	350	-23.47 (-38.82 to -8.12)	99	
72 h	2	140	-31.55 (-40.54 to -22.57)	95	

GRADE, Grades of Recommendation, Assessment, Development, and Evaluation; POCD, postoperative cognitive dysfunction.

0.62), p < 0.00001, $I^2 = 0\%$], 3 [OR = 0.43 (95% CI: 0.39, 0.62), p < 0.00001, $I^2 = 0\%$], and 7 [OR = 0.42 (95% CI: 0.26, 0.69), p = 0.0005, $I^2 = 0\%$], with no heterogeneity and a fixedeffects model. In the medium and long term, EA compared to no treatment had an obvious effect on the reduction in incidence of POCD at postoperative month 3 [OR = 0.27 (95% CI: 0.12, 0.61), p = 0.002, $I^2 = 0\%$] and 6 [OR = 0.20 (95% CI: 0.07, 0.57), p = 0.002, $I^2 = 0\%$], with no heterogeneity and a fixedeffects model (Figure 3). Most importantly, subgroup analysis by the EA treatment times between the EA group (EG) and the control group (CG) showed that the incidence of POCD was significantly lower in the EG than that in the CG, whether it is EA treatment once intraoperative [OR = 0.38 (95% CI: 0.29, 0.50), p < 0.00001, $I^2 = 0\%$] or multiple EA treatment in perioperative period [OR = 0.41 (95% CI: 0.29, 0.60), p $< 0.00001, I^2 = 0\%$] (Supplementary Figure 2). Furthermore, anesthesia method, as an important risk factor for POCD, was considered for subgroup analysis, and the result indicated that the EG presented a significant reduction in the incidence of POCD both general anesthesia [OR = 0.46 (95% CI: 0.36, 0.60), p < 0.00001, $I^2 = 0\%$] and spinal-epidural anesthesia [OR = 0.29 (95% CI: 0.19, 0.43), p < 0.00001, $I^2 = 0\%$], compared to the CG (**Supplementary Figure 3**).

Mini-Mental State Examination Scores

The MMSE score is one of the most common measurements for assessing cognitive function. A meta-analysis pooled from two trials (17, 18) involving 160 patients showed that there was no statistically significant difference in the improvement of the MMSE scores between the EG and the CG on the first postoperative day [MD = 1.77 (95% CI: -1.13, 4.67), p= 0.23, I^2 = 94%], with high heterogeneity and a randomeffects model. By contrast, a meta-analysis of 4 studies (17-20) revealed that, when compared to the CG, EA significantly improved the MMSE scores on the third postoperative day [MD = 2.21 (95% CI: 1.19, 3.23), p < 0.0001, I^2 = 84%], with substantial heterogeneity and a random-effects model (**Figure 4**).

100					Odds Ratio		Risk of Bias
	Total E	vents	Total	Weight	M-H, Fixed, 95% CI	M-H, Fixed, 95% Cl	ABCDEFG
1							
9	43	16	45	4.6%	0.48 [0.18, 1.25]		$\bullet ? ? \bullet \bullet ? \bullet$
12	30	20	30	4.5%	0.33 [0.12, 0.96]		$\bullet ? ? \bullet ? ? \bullet$
5	60	13	60	4.5%	0.33 [0.11, 0.99]		
27	50	33	50	5.7%	0.60 [0.27, 1.36]	+	$\bullet ? ? \bullet ? ? \bullet$
8	41	19	47	5.3%	0.36 [0.14, 0.94]		? ? ? . ? ? .
7	45	19	45	6.0%	0.25 [0.09, 0.69]		? ? ? + + ? +
8	30	9	30	2.5%	0.85 [0.28, 2.61]		$\mathbf{+} \mathbf{+} \mathbf{+} \mathbf{+} \mathbf{+} \mathbf{?} \mathbf{+}$
	299		307	33.1%	0.43 [0.30, 0.62]	•	
76		129					
			0%				
3							
	42	20	42	5.7%	0.34 [0.14, 0.87]		+??+??+
							+ $?$ $+$ $?$ $+$ $?$ $+$
							+ $?$ $+$ $?$ $+$ $?$ $+$
							+ $?$ $+$ $+$ $?$ $+$
							•• •????
	50		50			+	\bullet ? ? \bullet ? ? \bullet
0	322	14	322			◆	
65		114		011070			
	(P = 0.8)		0%				
			0 78				
4	43	7	45	2.3%	0.56 [0.15, 2.06]		$\bullet ? ? \bullet \bullet ? \bullet$
7	42	16	42	5.0%			$\bullet ? ? \bullet ? ? \bullet$
1	30	2	30	0.7%	0.48 [0.04, 5.63]		$\bullet ? ? \bullet ? ? \bullet$
6	40	15	40	4.8%	0.29 [0.10, 0.86]		$\bullet ? ? \bullet \bullet ? \bullet$
0	60	1	60	0.6%	0.33 [0.01, 8.21]		•••••••••••••••••••••••••••••••••••••••
3	50	4	50	1.4%	0.73 [0.16, 3.46]		$\bullet ? ? \bullet ? + $
4	41	8	47	2.5%	0.53 [0.15, 1.90]		? ? ? + ? ? +
3	45	6	45	2.1%	0.46 [0.11, 1.98]		<mark>????++?</mark> +
	351		359	19.4%	0.42 [0.26, 0.69]	◆	
28		59					
			0%				
		-,					
	12	14	12	1 6%	0 27 10 00 0 841		$\bullet ? ? \bullet ? ? \bullet$
							$+$ $\overline{?}$ $+$ $\overline{?}$ $+$ $\overline{?}$ $+$
4		12					
0	02	26	02	0.7 /0	0.27 [0.12, 0.01]	•	
-	(P - 0.0)		0%				
			0 78				
2		9					
_	82		82	7.0%	0.20 [0.07, 0.57]		
-	-						
			0%				
	1136		1152	100.0%	0.40 [0.32, 0.49]	♦	
183		348			_		
	25 (P =)	0.99); l²	= 0%				+
8.36 (P	< 0.000	01)		57) $l^2 = 0^9$	4	0.01 0.1 1 10 1 Favours [EG] Favours [CG]	100
	- 2.91	, ui – 4	(i = 0.	.57), 1 = 09	•		
noretic	(oclost	on his-	、 、				
			,				
		,	nonoc	biac)			
				ulas)			
			a5)				
ata (attr porting b		>)					
A 11 11 1 1 1 1	uas)						
, and the second s							
, and the second s							
	9 12 5 27 8 7 8 7 8 7 8 7 8 7 8 7 3 10 6 9 9 1 21 9 65 6 4.452 (F 3 10 6 9 9 1 21 9 65 6 4.46 (F 7 4 7 3 4 7 3 4 7 3 4 7 3 4 7 3 4 7 3 4 7 3 4 7 3 4 7 3 4 7 3 4 7 3 4 7 3 4 7 3 4 7 3 4 7 3 4 7 3 4 7 3 4 6 7 3 4 7 3 4 7 3 4 6 7 3 4 7 3 4 6 7 3 4 6 7 3 4 6 7 3 4 6 7 3 4 6 7 3 4 6 7 3 4 6 7 3 4 6 7 3 4 6 7 3 4 6 7 3 4 6 7 3 4 6 7 3 4 6 7 3 4 6 7 3 4 6 7 3 4 6 7 3 4 6 7 3 4 6 7 3 4 6 7 7 3 4 6 7 7 3 4 6 7 7 3 4 6 7 7 3 4 6 7 7 3 4 6 7 7 3 4 6 7 7 3 4 6 7 7 3 4 6 7 7 3 4 6 7 7 3 4 6 7 7 3 4 6 7 7 3 4 6 7 7 3 4 6 7 7 3 4 6 7 7 3 4 6 7 7 3 4 6 7 7 3 4 6 7 7 3 4 6 7 7 3 7 6 7 7 3 4 6 7 7 7 3 7 6 7 7 7 8 3 6 7 7 8 8 3 6 7 8 8 8 8 8 8 8 8 8 8 8 8 8	9 43 12 30 5 60 27 50 8 41 7 45 8 30 299 76 3, df = 6 (P = 0.7 4.52 (P < 0.000 3 10 42 6 40 9 60 9 40 1 60 21 50 9 30 322 65 7, df = 6 (P = 0.8 4.46 (P < 0.000 7 4 43 7 42 1 30 6 40 0 60 3 50 4 46 (P < 0.000 7 4 43 7 42 1 30 6 40 0 60 3 50 4 41 3 45 351 28 1, df = 7 (P = 0.9 3.46 (P = 0.000 13 50 4 41 3 45 351 28 1, df = 7 (P = 0.9 3.46 (P = 0.000 13 50 4 41 3 45 351 28 3.46 (P = 0.000 13 50 4 41 3 45 351 28 3.46 (P = 0.000 13 3 3 45 3.46 (P = 0.000 13 3 3 42 2 40 82 5 3.46 (P = 0.002 1136 183 3.04 (P = 0.000 1136 183 3.04 (P = 0.000 183 3.04 (P = 0.000 193 193 193 193 193 193 193 193	$\begin{array}{ccccccc} 9 & 43 & 16 \\ 12 & 30 & 20 \\ 5 & 60 & 13 \\ 27 & 50 & 33 \\ 8 & 41 & 19 \\ 7 & 45 & 19 \\ 8 & 30 & 9 \\ 299 \\ 76 & 129 \\ 299 \\ 76 & 129 \\ 4.52 (P < 0.00001) \\ 3 \\ 10 & 42 & 20 \\ 6 & 40 & 11 \\ 9 & 60 & 16 \\ 9 & 40 & 19 \\ 1 & 60 & 7 \\ 21 & 50 & 27 \\ 9 & 30 & 14 \\ 322 \\ 65 & 114 \\ 7 & df = 6 (P = 0.84); I^2 = \\ 4.46 (P < 0.00001) \\ 7 \\ 4 & 43 & 7 \\ 7 & 42 & 16 \\ 1 & 30 & 2 \\ 6 & 40 & 15 \\ 0 & 60 & 1 \\ 3 & 50 & 4 \\ 4 & 41 & 8 \\ 3 & 45 & 6 \\ 351 \\ 28 & 59 \\ 1, df = 7 (P = 0.98); I^2 = \\ 3.46 (P = 0.0005) \\ \text{nth 3} \\ 5 & 42 & 14 \\ 4 & 40 & 12 \\ 82 \\ 9 & 26 \\ 0, df = 1 (P = 0.96); I^2 = \\ 3.12 (P = 0.002) \\ \text{nth 6} \\ 3 & 42 & 11 \\ 2 & 40 & 9 \\ 82 \\ 5 & 20 \\ 3.04 (P = 0.002) \\ \text{nth 6} \\ 136 & 348 \\ 13, df = 25 (P = 0.98); I^2 = \\ 3.04 (P = 0.002) \\ \text{ntraded} \\ 136 & 348 \\ 13, df = 25 (P = 0.99); I^2 = \\ 3.04 (P = 0.002) \\ \text{ntraded} \\ 136 & 348 \\ 13, df = 25 (P = 0.99); I^2 = \\ 3.04 (P = 0.002) \\ \text{ntraded} \\ 136 & 348 \\ 136 & 412 \\ 136 & 348 \\ 136 & 412 \\ 136 & 348 \\ 136 & 412 \\ 136 & 348 \\ 136 & 412 \\ 136 & 348 \\ 136 & 412 \\ 136 & 348 \\ 136 & 412 \\ 136 & 348 \\ 136 & 412 \\ 136 & 348 \\ 136 & 412 \\ 136 & 348 \\ 136 & 412 \\ 136 & 348 \\ 136 & 412 \\ 136 & 348 \\ 136 & 412 \\ 136 & 348 \\ 136 & 412 \\ 136 & 348 \\ 136 & 412 \\ 136 & 348 \\ 136 & 412 \\ 136 & 348 \\ 136 & 412 \\ 136 & 348 \\ 136 & 412 \\ 146$	$\begin{array}{ccccccc} 9 & 43 & 16 & 45 \\ 12 & 30 & 20 & 30 \\ 5 & 60 & 13 & 60 \\ 27 & 50 & 33 & 50 \\ 8 & 41 & 19 & 47 \\ 7 & 45 & 19 & 45 \\ 8 & 30 & 9 & 30 \\ 299 & 307 \\ 76 & 129 \\ 3, df = 6 (P = 0.70); ^2 = 0\% \\ 4.52 (P < 0.00001) \\ \hline 3 \\ 10 & 42 & 20 & 42 \\ 6 & 40 & 11 & 40 \\ 9 & 60 & 16 & 60 \\ 9 & 40 & 19 & 40 \\ 1 & 60 & 7 & 60 \\ 21 & 50 & 27 & 50 \\ 9 & 30 & 14 & 30 \\ 322 & 322 \\ 65 & 114 \\ 7, df = 6 (P = 0.84); ^2 = 0\% \\ 4.46 (P < 0.00001) \\ \hline 7 \\ 4 & 43 & 7 & 45 \\ 7 & 42 & 16 & 42 \\ 1 & 30 & 2 & 30 \\ 6 & 40 & 15 & 40 \\ 0 & 60 & 1 & 60 \\ 3 & 50 & 4 & 50 \\ 4 & 41 & 8 & 47 \\ 3 & 45 & 6 & 45 \\ 351 & 359 \\ 28 & 59 \\ 1, df = 7 (P = 0.98); ^2 = 0\% \\ 3.46 (P = 0.005) \\ \text{nth 3} \\ 5 & 42 & 14 & 42 \\ 4 & 40 & 12 & 40 \\ 82 & 82 \\ 9 & 26 \\ 0, df = 1 (P = 0.96); ^2 = 0\% \\ 3.12 (P = 0.002) \\ \text{nth 6} \\ 3 & 42 & 11 & 42 \\ 2 & 40 & 9 & 40 \\ 82 & 82 \\ 5 & 20 \\ 3.04 (P = 0.002) \\ \hline 1136 & 1152 \\ 183 & 348 \\ 13, df = 25 (P = 0.99); ^2 = 0\% \\ 8.36 (P < 0.00001) \\ \text{ces: Chi^2 = 2.91, df = 4 (P = 0) \\ \text{neration (selection bias)} \\ \text{t} (selection bias) \\ \text{t} (select$	9 43 16 45 4.6% 12 30 20 30 4.5% 5 60 13 60 4.5% 27 50 33 50 5.7% 8 41 19 47 5.3% 7 45 19 45 6.0% 8 30 9 30 2.5% 299 307 33.1% 76 129 3, df = 6 (P = 0.70); $ ^2 = 0\%$ 4.52 (P < 0.00001) 3 10 42 20 42 5.7% 6 40 11 40 3.5% 9 60 16 60 5.1% 9 40 19 40 5.5% 1 60 7 60 2.6% 21 50 27 50 5.9% 9 30 14 30 3.7% 322 322 31.9% 65 114 7, df = 6 (P = 0.84); $ ^2 = 0\%$ 4.46 (P < 0.00001) 7 4 43 7 45 2.3% 7 42 16 42 5.0% 1 30 2 30 0.7% 6 40 15 40 4.8% 0 60 1 60 0.6% 3 50 4 50 1.4% 4 41 8 47 2.5% 3 45 6 45 2.1% 3 51 359 19.4% 28 59 1, df = 7 (P = 0.98); $ ^2 = 0\%$ 3.46 (P = 0.0005) nth 3 5 42 14 42 4.6% 4 40 12 40 4.0% 82 82 8.7% 9 26 0, df = 1 (P = 0.96); $ ^2 = 0\%$ 3.12 (P = 0.96); $ ^2 = 0\%$ 3.12 (P = 0.002) nth 6 3 42 11 42 3.8% 2 40 9 40 3.2% 82 82 7.0% 5 20 3, df = 1 (P = 0.87); $ ^2 = 0\%$ 3.04 (P = 0.002) 1136 1152 100.0% 183 348 13, df = 25 (P = 0.99); $ ^2 = 0\%$ 3.04 (P = 0.0001) ces: Chi ² = 2.91, df = 4 (P = 0.57), $ ^2 = 0\%$ 8.36 (P < 0.00001) ces: Chi ² = 2.91, df = 4 (P = 0.57), $ ^2 = 0\%$ 8.36 (P < 0.00001) ces: Chi ² = 2.91, df = 4 (P = 0.57), $ ^2 = 0\%$ 8.36 (P < 0.00001) ces: Chi ² = 2.91, df = 4 (P = 0.57), $ ^2 = 0\%$ 8.36 (P < 0.00001) ces: Chi ² = 2.91, df = 4 (P = 0.57), $ ^2 = 0\%$ 8.36 (P < 0.00001) ces: Chi ² = 2.91, df = 4 (P = 0.57), $ ^2 = 0\%$ 8.36 (P < 0.00001) ces: Chi ² = 2.91, df = 4 (P = 0.57), $ ^2 = 0\%$ 8.36 (P < 0.00001) ces: Chi ² = 2.91, df = 4 (P = 0.57), $ ^2 = 0\%$	$\begin{array}{cccccccccccccccccccccccccccccccccccc$	9 43 16 45 4.8% 0.48 [0.18, 125] 12 30 20 30 4.5% 0.33 [0.20.96] 5 60 13 60 4.5% 0.33 [0.20.96] 7 61 19 47 5.3% 0.60 [0.27, 1.36] 7 41 19 47 5.3% 0.36 [0.26, 0.9, 0.69] 7 45 19 45 6.0% 0.25 [0.9, 0.69] 7 45 19 45 6.0% 0.25 [0.9, 0.69] 7 45 129 307 33.1% 0.45 [0.30, 0.62] 7 5 129 9 307 33.1% 0.45 [0.30, 0.62] 7 6 129 9 40 19 40 5.5% 0.32 [0.10, 0.51, 1.41] 9 40 19 40 5.5% 0.32 [0.12, 0.84] 1 60 7 60 2.6% 0.13 [0.02, 1.08] 1 60 7 60 2.6% 0.13 [0.02, 1.08] 1 60 7 60 2.6% 0.48 [0.47, 1.41] 9 40 19 40 5.5% 0.47 [0.17, 1.41] 3 22 322 31.9% 0.45 [0.29, 0.62] 65 114 7 42 16 42 5.0% 0.33 [0.12, 0.90] 1 30 2 30 0.7% 0.48 [0.47, 6.346] 7 42 16 42 5.0% 0.33 [0.12, 0.90] 1 30 2 30 0.7% 0.48 [0.47, 6.346] 7 42 16 42 5.0% 0.33 [0.12, 0.90] 1 30 2 30 0.7% 0.48 [0.47, 6.346] 0 60 1 60 0.6% 0.33 [0.10, 8.21] 7 44 3 7 45 2.3% 0.56 [0.15, 2.06] 7 42 16 42 5.0% 0.33 [0.10, 8.21] 65 114 7 42 16 42 5.0% 0.33 [0.10, 8.21] 7 44 3 7 45 2.3% 0.56 [0.15, 2.06] 1 30 2 30 0.7% 0.48 [0.47, 1.41] 3 25 35 19.4% 0.42 [0.26, 0.69] 3 45 0 45 0 1.4% 0.73 [0.16, 3.46] 0 60 1 60 0.6% 0.33 [0.10, 8.21] 3 50 4 50 1.4% 0.73 [0.16, 3.46] 1 40 12 40 0.% 0.26 [0.08, 0.89] 82 82 8.7% 0.27 [0.09, 0.84] 4 40 12 40.9% 0.26 [0.08, 0.89] 82 82 82 7.0% 0.26 [0.08, 0.89] 82 82 82 7.0% 0.26 [0.07, 0.57] 5 20 3.46 (P = 0.096); P = 0% 3.46 (P = 0.096); H = 0% 3.46 (P = 0.096); H = 0% 3.46 (P = 0.097); P = 0% 3.66 (P = 0.090) = 1 = 0% 82 82 7.0% 0.20 [0.07, 0.57] 5 20 3.64 (P = 0.092) = 1 = 0% 3.64 (P = 0.097); P = 0% 3.64 (P = 0.097); P = 0% 3.64 (P = 0.097); P = 0% 3.64 (P = 0.099); P = 0% 3.64 (P = 0.097); P = 0% 3.64 (P = 0.0

Relevant Serum Indexes Including NSE, S100 β , IL-1 β , and TNF- α

A total of six trials (18-20, 22, 26, 27) reported EA preconditioning for effects of serum indexes including NSE,

S100 β , IL-1 β , and TNF- α . From a fixed-effects model, the pooled data from two trials (20, 22) suggested that EA significantly decreased the NSE expression level at postoperative hours 0 [MD = -0.35 (95% CI: -0.69 to -0.02), p = 0.04, $l^2 = 0\%$], 24 [MD

		EG			CG			Mean Difference	Mean Difference	Risk of Bias
tudy or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	IV, Random, 95% Cl	ABCDEFG
.3.1 post-operative	day 1									
u (2019)	21.35	2.72	50	18.12	1.53	50	17.0%	3.23 [2.36, 4.10]		+??+??+
hao (2018)	27.1	1.95	30	26.83	2.25	30	15.8%	0.27 [-0.80, 1.34]		$\mathbf{+} \mathbf{+} \mathbf{+} \mathbf{+} \mathbf{+} \mathbf{?} \mathbf{+}$
ubtotal (95% CI)			80			80	32.8%	1.77 [-1.13, 4.67]		
eterogeneity: Tau ² =	4.14; Cł	ni² = 17	7.87, df	= 1 (P	< 0.000	01); l² =	94%			
est for overall effect:				,		,.				
3.2 post-operative	day 3									
iu (2017)	24.3	1.8	40	22.9	1.7	40	17.5%	1.40 [0.63, 2.17]		+??+??+
iu (2018)	24.1	1.9	60	22.1	1.8	60	18.0%	2.00 [1.34, 2.66]		+??+??+
u (2019)	25.73	1.57	50	22.15	2.13	50	17.7%	3.58 [2.85, 4.31]		+??+??+
hao (2018)	26.53	2.26	30	24.79	3.03	30	14.1%	1.74 [0.39, 3.09]		+++++?+
ubtotal (95% CI)			180			180	67.2%	2.21 [1.19, 3.23]	-	
eterogeneity: Tau ² =	0.89; Cł	ni² = 18	3.42, df	= 3 (P	= 0.000	04); l² =	84%			
est for overall effect:	Z = 4.23	(P < (0.0001)							
otal (95% Cl)			260			260	100.0%	2.07 [1.12, 3.02]	•	
eterogeneity: Tau ² =	1.19; Cł	ni² = 3€	5.61. df	= 5 (P	< 0.000	001); l²	= 86%			_
est for overall effect:						,,			-4 -2 0 2 4	
est for subgroup diffe		•	,		P = 0.78	3), ² = (0%		Favours [CG] Favours [EG]	
and and and and			, .	. (.	0.11					

		EG			CG			Mean Difference	Mean Difference	Risk of Bias
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% CI	IV, Fixed, 95% Cl	ABCDEFG
1.4.1 post-operative	hour 0									
Li (2016)	7.7	2.2	18	8.8	2.6	18	2.3%	-1.10 [-2.67, 0.47]		+??+??+
Liu (2017)	4.63	0.74	40	4.95	0.81	40	48.2%	-0.32 [-0.66, 0.02]		+??+??+
Subtotal (95% CI)			58			58	50.5%	-0.35 [-0.69, -0.02]	•	
Heterogeneity: Chi ² =	0.90, df	= 1 (P	= 0.34)	; l² = 0%	6					
Test for overall effect:	Z = 2.09) (P = (0.04)							
1.4.2 post-operative	hour 24									
Li (2016)	8.4	3.3	18	11.1	3.5	18	1.1%	-2.70 [-4.92, -0.48]	<u> </u>	+??+??+
Liu (2017)	5.36	1.04	40	7.53	1.26	40	21.7%	-2.17 [-2.68, -1.66]	T	+??+??+
Subtotal (95% CI)			58			58	22.9%	-2.20 [-2.69, -1.70]	•	
Heterogeneity: Chi ² =	0.21, df	= 1 (P	= 0.65)	; ² = 0%	6					
Test for overall effect:	Z = 8.72	? (P < (0.00001)						
1.4.3 post-operative	hour 48									
Li (2016)	7.1	2.8	18	9.6	3.4	18	1.3%	-2.50 [-4.53, -0.47]		+??+??+
Liu (2017)	5.22	0.96	40	6.38	1.17	40	25.3%	-1.16 [-1.63, -0.69]		+??+??+
Subtotal (95% CI)			58			58	26.7%	-1.23 [-1.68, -0.77]	◆	
Heterogeneity: Chi ² =	1.58, df	= 1 (P	= 0.21)	; l² = 37	%					
	Z = 5.26) (P < (0.00001)						
Test for overall effect:						474	100 0%	-1.01 [-1.24, -0.77]	♦	
Test for overall effect: Total (95% CI)			174			1/4	100.0 /0	-1.01 [-1.24, -0.77]		
	40.67, d	f = 5 (F		0001); ľ	² = 88%		100.0 %	-1.01[-1.24, -0.77]		_
Total (95% CI)		,	P < 0.00		² = 88%		100.0 %	-1.01 [-1.24, -0.77] -	-4 -2 0 2 4 Favours [EG] Favours [CG]	_

		EG			CG			Mean Difference	Mean Difference	Risk of Bias
Study or Subgroup		SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	IV, Random, 95% Cl	ABCDEFG
1.5.1 post-operative h	our 0									
Li (2016)	0.96	0.37	18	1.44	0.59	18	1.3%	-0.48 [-0.80, -0.16]		+??+??+
Liu (2017)	0.45	0.26	40	0.63	0.32	40	5.8%	-0.18 [-0.31, -0.05]		+??+??+
Zhang (2012)	0.25	0.1	25	0.25	0.13	30	11.2%	0.00 [-0.06, 0.06]	+	???+??+
Zhang (2014)	0.25	0.1	45	0.26	0.09	45	13.4%	-0.01 [-0.05, 0.03]		? ? ? + + ? +
Subtotal (95% CI)			128			133	31.7%	-0.08 [-0.18, 0.02]	•	
Heterogeneity: Tau ² =	0.01; Ch	1i² = 14	.52, df	= 3 (P	= 0.00	2); l² =	79%			
Test for overall effect: 2	Z = 1.63	(P = 0).10)							
1.5.2 post-operative h	our 24									
Li (2016)	0.6	0.23	18	0.85	0.3	18	3.7%	-0.25 [-0.42, -0.08]		+??+??+
Liu (2017)	0.31	0.21	40	0.38	0.23	40	7.9%	-0.07 [-0.17, 0.03]		+??+??+
Zhang (2012)	0.23	0.09	25	0.22	0.11	30	12.0%	0.01 [-0.04, 0.06]	+	? ? ? + ? ? +
Zhang (2014)	0.24	0.13	45	0.26	0.11	45	12.4%	-0.02 [-0.07, 0.03]	*	? ? ? + + ? +
Zhao (2018)	0.38	0.34	30	0.49	0.42	30	3.2%	-0.11 [-0.30, 0.08]		$\mathbf{+} \mathbf{+} \mathbf{+} \mathbf{+} \mathbf{+} \mathbf{?} \mathbf{+}$
Subtotal (95% CI)			158			163	39.3%	-0.05 [-0.11, 0.01]	•	
Heterogeneity: Tau ² =				= 4 (P =	0.05);	² = 59	%			
Test for overall effect: 2	Z = 1.59	(P = 0).11)							
1.5.3 post-operative h	our 48									
Li (2016)	0.8	0.26	18	1.09	0.45	18	2.2%	-0.29 [-0.53, -0.05]		$\bullet ? ? \bullet ? ? \bullet$
Liu (2017)	0.25	0.18	40	0.31	0.19	40	9.2%	-0.06 [-0.14, 0.02]		+ ? ? + ? ? +
Subtotal (95% CI)			58			58	11.5%	-0.15 [-0.36, 0.07]		
Heterogeneity: Tau ² =	0.02; Cł	1i² = 3.1	16, df =	= 1 (P =	0.08);	² = 68	%			
Test for overall effect: 2	Z = 1.31	(P = 0).19)							
1.5.4 post-operative h	our 72									
Liu (2017)	0.2	0.14	40	0.21	0.11	40	11.8%	-0.01 [-0.07, 0.05]	*	+??+??+
Zhao (2018)	0.28	0.2	30	0.41	0.3	30	5.7%	-0.13 [-0.26, -0.00]		$\mathbf{+} \mathbf{+} \mathbf{+} \mathbf{+} \mathbf{+} \mathbf{?} \mathbf{+}$
Subtotal (95% CI)			70			70	17.5%	-0.06 [-0.17, 0.06]	•	
Heterogeneity: Tau ² =	0.00; Cł	ni² = 2.8	81, df =	= 1 (P =	0.09);	² = 64	%			
Test for overall effect: 2	Z = 0.95	(P = 0).34)							
Total (95% Cl)			414			424	100.0%	-0.06 [-0.10, -0.02]	•	
Heterogeneity: Tau ² = 0	0.00; Cł	1i² = 32	2.33, df	= 12 (F	9 = 0.0	01); l² =	63%			H .
	Z = 2.95	(P = 0)).003)	``					-1 -0.5 0 0.5 Favours [EG] Favours [CG]	1
Test for overall effect: 2										

= -2.20 (95% CI: -2.69 to -1.70), p < 0.00001, $I^2 = 0\%$], and 48 [MD = -1.23 (95% CI: -1.68 to -0.77), p < 0.00001, I^2 = 37%], with low heterogeneity (Figure 5). A meta-analysis for S100ß failed to demonstrate significant difference between the EG and the CG at postoperative hours 0 [MD = -0.08 (95% CI: -0.18 to 0.02), p = 0.10, $I^2 = 79\%$], 24 [MD = -0.05 (95% CI: -0.11 to 0.01), p = 0.11, $I^2 = 59\%$], 48 [MD = -0.15 (95% CI: -0.36 to 0.07), p = 0.19, $I^2 = 68\%$], and 72 [MD = -0.06 (95%) CI: -0.17 to 0.06), p = 0.34, $I^2 = 64\%$] and the number of articles included in the subgroup analysis was 4 (20-27), 5 (18-27), 2 (20-22), and 2 (18-20), respectively (Figure 6). With respect to IL-1 β , a meta-analysis that included 3 (19–26), 4 (18–26), and 2 studies (18–20), respectively, revealed lower IL-1 β levels in the EG compared to the CG at postoperative hours 0 [MD = -1.72(95% CI: -3.28 to -0.16), p = 0.03, $I^2 = 53\%$], 24 [MD = -16.43 (95% CI: -28.43 to -4.43), p = 0.007, $I^2 = 99\%$], and 72 [MD = -31.99 (95% CI: -46.04 to -17.94), p < 0.00001, $I^2 =$ 97%], with substantial heterogeneity and a random-effects model (**Figure 7**). With respect to TNF- α , no significant differences have been observed between the EG and the CG at postoperative hour 0 [MD = -2.35 (95% CI: -4.88 to 0.18), p = 0.07, $I^2 = 81\%$]. It is with a remarkable reduction in the EG in contrast to the CG at postoperative hours 24 [MD = -23.47 (95% CI: -38.82 to -8.12), p = 0.003, $l^2 = 99\%$] and 48 [MD = -31.55 (95% CI: -40.54 to -22.57), p < 0.00001, $l^2 = 95\%$], with substantial heterogeneity and a random-effects model (**Figure 8**).

Sensitivity Analysis

Although subgroup analyses were done based on different observation times, the heterogeneity of some outcomes remained high ($I^2 = 86\%$, 99 and 99% for the MMSE scores, IL-1 β , and TNF- α , respectively). Therefore, a method of one study excluded at a time was used to detect the source of heterogeneity and to assess whether the results could have been influenced. The results showed that there was no significant influence on the pooled MD value and the overall heterogeneities (**Supplementary Table 1**).

Publication Bias

No evidence for significant publication bias was detected by Begg's test and Egger's test among the included studies (**Supplementary Table 2**).

		EG			CG			Mean Difference	Mean Difference	Risk of Bias
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	IV, Random, 95% Cl	ABCDEFG
1.6.1 post-operative h										
_iu (2017)	48.6		40	49.2		40	11.2%	-0.60 [-2.22, 1.02]	1	+??+??+
_iu (2018)	49.5	3.7	60	52.3	3.8	60	11.2%	-2.80 [-4.14, -1.46]	-	+??+??+
Zhang (2014)	32.45	8.24	45	33.91	6.38	45	11.1%	-1.46 [-4.50, 1.58]	-	<mark>???++?+</mark>
Subtotal (95% CI)			145			145	33.4%	-1.72 [-3.28, -0.16]	•	
Heterogeneity: Tau ² =				= 2 (P = 0).12); I	² = 53%	þ			
Test for overall effect:	Z = 2.16	6 (P = 0	0.03)							
1.6.2 post-operative h	nour 24									
_iu (2017)	75.3	4.9	40	95.6	5.8	40	11.1%	-20.30 [-22.65, -17.95]	+	+??+??+
_iu (2018)	77.8	5.1	60	106.5	6	60	11.1%	-28.70 [-30.69, -26.71]	-	+??+??+
Zhang (2014)	26.37	4.53	45	25.13	5.03	45	11.1%	1.24 [-0.74, 3.22]	-	???++?+
Zhao (2018)	73.13	2.32	30	91.1	3.55	30	11.2%	-17.97 [-19.49, -16.45]		$\bullet \bullet \bullet \bullet \bullet \bullet \circ \circ \bullet$
Subtotal (95% CI)			175			175	44.6%	-16.43 [-28.43, -4.43]		
Heterogeneity: Tau ² =	148.90;	Chi² =	466.64	l, df = 3 (P < 0.	00001)	l² = 99%			
Test for overall effect:	Z = 2.68	3 (P = 0	0.007)							
1.6.3 post-operative h	nour 72									
_iu (2017)	84.4	5.2	40	123.5	7.8	40	11.1%	-39.10 [-42.01, -36.19]	-	$\bullet ? ? \bullet ? ? \bullet$
Zhao (2018)	87.17	5.95	30	111.93	9.18	30	11.0%	-24.76 [-28.67, -20.85]	-	$\mathbf{+}\mathbf{+}\mathbf{+}\mathbf{+}\mathbf{+}\mathbf{?}\mathbf{+}$
Subtotal (95% CI)			70			70	22.0%	-31.99 [-46.04, -17.94]	\bullet	
Heterogeneity: Tau ² =	99.72; (Chi² = 3	3.24, d	lf = 1 (P	< 0.00	001); l²	= 97%			
Test for overall effect:	Z = 4.46	; (P < 0	.00001)						
Total (95% CI)			390			390	100.0%	-14.91 [-23.55, -6.27]	•	
Heterogeneity: Tau ² =	173.34:	Chi ² =	1336.4	6. df = 8	(P < (0.00001): $ ^2 = 999$			
							,,		-50 -25 0 25	50
Test for overall effect:							= 91.3%		Favours [EG] Favours [CG]	

FIGURE 7 | Meta-analysis and forest plot and for interleukin-1β (IL-1β) at different periods

Evidence Quality Assessment

The quality of the evidence was assessed by the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) system. The summary of findings indicated that there was low certainty in the incidence of POCD, moderate certainty in the MMSE scores, and very low certainty in NSE, S100 β , IL-1 β , and TNF- α levels (**Supplementary Figure 4**).

Adverse Events

A total of four studies (18, 22, 24, 27) paid attention to adverse events. Three of four studies (18, 22, 24) merely stated that no serious adverse events were observed in their trial. One study (27) reported in detail that the number of patients with postoperative nausea and vomiting and pulmonary infection in the EG was 5 and 4, respectively and in the CG, the number of patients with postoperative nausea and vomiting, and pulmonary infection were 6 and 5, respectively.

DISCUSSION

In recent years, a higher incidence of POCD has been found in elderly patients with total joint replacement. Until now, available means to prevent and cure POCD are still lacking. Some studies have demonstrated that EA is beneficial to restore the homeostatic balance of nerve function and it has been suggested to prevent POCD. In this study, we investigated the effect of EA against POCD in an elderly patient undergoing total joint replacement. We included eleven RCTs with a total of 949 patients and found that EA therapy was effective in protecting cognitive function during total joint replacement surgery in the aged patient. First, EA pretreatment significantly reduced the incidence of POCD at different observation times after surgery compared to sham EA and no treatment, and the consistent results were found in the subgroup analysis of EA treatment times and anesthesia method. Second, EA therapy was superior to no treatment in improving the MMSE scores on the third postoperative day, but not on the first postoperative day. Finally, EA decreased the levels of NSE and IL-1 β at an early stage after the operation. But, no substantial effects were observed for S100 β . In terms of TNF- α , EA did not show any significant improvement at postoperative hour 0, while the results reversed at postoperative hours 24 and 48. In addition, EA did not increase or decrease adverse events.

Postoperative cognitive dysfunction is associated with a variety of risk factors such as surgery-, anesthesia-, and patient-related factors. Among these, the effect of the operation type in POCD remains arguable. Previous studies showed that a higher incidence of POCD in patients undergoing cardiac surgery than

		EG			CG			Mean Difference	Mean Difference	Risk of Bias
Study or Subgroup	Mean	SD	Iotal	Mean	SD	lotal	Weight	IV, Random, 95% CI	IV, Random, 95% Cl	ABCDEFG
1.7.1 post-operative h										
₋iu (2017)	60.1	4.1	40	63.8		40	11.1%	-3.70 [-5.54, -1.86]		+??+??+
∟iu (2018)	60.1	4.1	60	63.8			11.2%	-3.70 [-5.20, -2.20]	•	+??+??+
Zhang (2014)	41.92	6.34	45	41.01	6.05	45	11.1%	0.91 [-1.65, 3.47]		???++?+
Subtotal (95% CI)			145			145	33.4%	-2.35 [-4.88, 0.18]	•	
Heterogeneity: Tau ² =	,		,	= 2 (P =	0.006); l² = 8	1%			
Test for overall effect:	Z = 1.82	? (P = 0	.07)							
1.7.2 post-operative h	our 24									
_iu (2017)	92.4	5.6	40	124.3	7.9	40	11.1%	-31.90 [-34.90, -28.90]	-	+??+??+
_iu (2018)	92.6	5.6	60	128.2	8.1	60	11.1%	-35.60 [-38.09, -33.11]	+	+??+??+
Zhang (2014)	35.17	5.99	45	33.99	6.23	45		1.18 [-1.35, 3.71]	+	???++?+
Zhao (2018)	88.8	3.55	30	116.37	3.14	30	11.1%	-27.57 [-29.27, -25.87]		$\mathbf{+} \mathbf{+} \mathbf{+} \mathbf{+} \mathbf{+} \mathbf{?} \mathbf{+}$
Subtotal (95% CI)			175			175	44.4%			
Heterogeneity: Tau ² =	243.86;	Chi² =	508.88	, df = 3 (P < 0.	00001);	; l ² = 99%			
Test for overall effect:	Z = 3.00) (P = 0	.003)							
1.7.3 post-operative ł	nour 72									
_iu (2017)	95.6	5.7	40	131.8	8.2	40	11.1%	-36.20 [-39.29, -33.11]	+	+??+??+
Zhao (2018)	94.37	5.22	30	121.4	3.68	30	11.1%	-27.03 [-29.32, -24.74]		$\mathbf{+} \mathbf{+} \mathbf{+} \mathbf{+} \mathbf{+} \mathbf{?} \mathbf{+}$
Subtotal (95% CI)			70			70	22.2%	-31.55 [-40.54, -22.57]	◆	
Heterogeneity: Tau ² =	40.12; C	Chi ² = 2	1.82, d	f = 1 (P	< 0.00	001); l²	= 95%			
Test for overall effect:	Z = 6.88	8 (P < 0	.00001)						
Fotal (95% CI)			390			390	100.0%	-18.16 [-28.26, -8.06]	•	
Heterogeneity: Tau ² =	237.51:	Chi² =	1548.7	0, df = 8	(P < (0.00001); l ² = 999	6		<u> </u>
Test for overall effect:					,				-50 -25 0 25	50
Test for subgroup diffe			,		< 0.0	0001). I	² = 95.4%		Favours [EG] Favours [CG]	

in patients with non-cardiac surgery (28). Recently, Evered et al. reported that the incidence of POCD in elderly patients at 3 months was not statistically significant between total hip joint replacement and coronary artery bypass graft surgery (29). It is reported that patients over the age of 65 years who underwent non-cardiac surgery had a 26% prevalence of POCD within a few weeks, which decreased to 10% in 3 months postoperatively (30). Of the 11 trials included, there were 7 trials about total hip replacement and 2 trials about total knee replacement and the other two trials were about total hip and knee arthroplasty. So far, no studies have demonstrated a difference in the incidence of POCD between total knee replacement and total hip replacement. Besides, the anesthesia technique is a potential risk factor for POCD. In general, regional anesthesia protects cognitive function better than general anesthesia (31). As for drug selection, Li et al. suggested that propofol sedation, compared to dexmedetomidine and midazolam sedation in elderly patients, shows a significant advantage in terms of short-term POCD incidence (32). In this study, only 2 of 11 studies were performed under spinal-epidural anesthesia and the rest were conducted under general anesthesia. Moreover, the number of trials using propofol and midazolam sedation was 10 and 9, respectively.

The effectiveness of EA for cognitive improvement has been demonstrated in various clinical and animal studies. The concrete mechanism involved in EA for POCD treatment may be related to improving cerebral blood perfusion and metabolism (33), antineuroinflammation (34, 35), antioxidant stress (3, 36), and activates sympathetic nerve fibers (37). At present, neuroinflammation plays an important role in the pathophysiology of cognitive impairment. Han et al. found that EA could enhance the expression of α 7-nicotinic acetylcholine receptor (a7-nAChR) and cholinergic factors and suppress neuroinflammation in the hippocampus (38). Recently, Liu et al. made a succession of in-depth studies on the neuroanatomical basis behind EA and found that EA stimulation drives sympathetic pathways in a somatotopyand intensity-dependent manner (39). Moreover, their findings showed that EA could activate neurons expressed a specific molecular marker, and provided a neuroanatomical basis for the selectivity and specificity of acupoints in driving specific autonomic pathways (40). EA pretreatment at "Baihui" (DU20) and "Dazhui" (DU14) may increase the learning and memory ability of POCD aged mice, which is probably related to the decrease of oxidative stress and the strengthening of hippocampal antioxidant capacity (41). In the theory of acupuncture, no excellent clinical effect can be acquired without proper acupoints selection. EA stimulation at specific acupoints could produce a therapeutic effect against POCD. Lin analyzed the application of acupoints in ancient literature and found that "Baihui" (DU20), "Shenting" (DU24), "Shendao" (DU11), "Quchi" (LI11), and "Shenmen" (HT7) were the top 5 of the acupoints application frequency in cognitive dysfunction treatment (42). For this article, "Baihui" (DU20) tied with "Shenting" (DU24) for the most selection with 5 times, which was consistent with the study above. A study reported that EA at "Baihui" (DU20) can obviously improve cognitive ability damaged by sevoflurane and its mechanism may be related to activation of Shh pathway (43). Moreover, stimulating parameters of EA could affect therapeutic effects. Among the 11 studies, there were 4 studies that selected 2–10 and 2– 15 Hz, respectively, and 2 studies that used 200 Hz. It is indicated that 10 Hz EA produces longer-lasting alleviation of inflammatory pain than 100 Hz and 2–10 Hz inhibit nerve injurycaused allodynia/hyperalgesia more potently than EA at 100 Hz (44).

Some limitations in this study are supposed to list. First, we did not include studies, which reported in non-Chinese or non-English languages, and all the studies were conducted in China. Second, the overall methodological quality of the included studies was low because of incorrect randomization and inadequate blinding, which reduced the validity of the analysis results. Third, inconsistency was detected in the acupoints and the EA stimulation parameters including frequency, intensity, and duration, which may contribute to high heterogeneity and affect the results. Future studies should improve the methodology quality and be consistent in acupuncture points and stimulation parameters.

CONCLUSION

In this study, the preventive effect of EA for POCD was systematically reviewed and quantified. For older patients undergoing hip and knee arthroplasty, EA pretreatment has a protective effect against POCD. EA can reduce the incidence of POCD (low evidence) and improve the MMSE scores (moderate evidence). In terms of relevant serum indexes, although EA precondition could not reduce the expression of S100 β (very low evidence), it significantly decreases levels of NSE (very low

REFERENCES

- Humeidan ML, Reyes JC, Mavarez-Martinez A, Roeth C, Nguyen CM, Sheridan E, et al. Effect of cognitive prehabilitation on the incidence of postoperative delirium among older adults undergoing major noncardiac surgery: the neurobics randomized clinical trial. *Jama Surg.* (2021) 156:148– 56. doi: 10.1001/jamasurg.2020.4371
- Lin X, Chen Y, Zhang P, Chen G, Zhou Y, Yu X. The potential mechanism of postoperative cognitive dysfunction in older people. *Exp Gerontol.* (2020) 130:110791. doi: 10.1016/j.exger.2019.110791
- Zhang D, Ying J, Ma X, Gao Z, Chen H, Zhu S, et al. Social cognitive dysfunction in elderly patients after anesthesia and surgery. *Front Psychol.* (2020) 11:541161. doi: 10.3389/fpsyg.2020.541161
- Yazit N, Juliana N, Das S, Teng N, Fahmy NM, Azmani S, et al. Association of microRNA and postoperative cognitive dysfunction: a review. *Mini Rev Med Chem.* (2020) 20:1781–90. doi: 10.2174/1389557520666200621182717
- 5. Xie Z, Tanzi RE. Alzheimer's disease and post-operative cognitive dysfunction. *Exp Gerontol.* (2006) 41:346–59. doi: 10.1016/j.exger.2006.01.014
- Kapila AK, Watts HR, Wang T, Ma D. The impact of surgery and anesthesia on post-operative cognitive decline and Alzheimer's disease development: biomarkers and preventive strategies. J Alzheimers Dis. (2014) 41:1–13. doi: 10.3233/JAD-132258

evidence), IL-1 β (very low evidence), and TNF- α (very low evidence). However, taking into consideration the limitation of this study, more large-scale, high-quality, and good-homogeneity RCTs are warranted.

DATA AVAILABILITY STATEMENT

The original contributions presented in the study are included in the article/**Supplementary Material**, further inquiries can be directed to the corresponding author/s.

AUTHOR CONTRIBUTIONS

LO, ZS, and ZC designed this study. LO and ZC generated the search strategy and accomplished the literature search and selection. DX and DK did the data extraction. LZ and QQ evaluated the quality assessment. TZ, YH, and WH performed data analysis and evaluated the certainty of evidence. LO drafted the first manuscript. YM revised the manuscript and supervised the study. All authors have read and approved the submitted version of the manuscript.

FUNDING

This study received funding from the following projects: the Scientific Research Projects of Guizhou Traditional Chinese Medicine Bureau (No. QZYY-2019-031), the National Innovation and Entrepreneurship Training Program for College Students (201910662), and the Evaluation Project for the Key Diseases of TCM Curative Effect of The Second Affiliated Hospital of Guizhou University of Chinese Medicine (GZEYK-Y[2021]5).

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fmed. 2021.778474/full#supplementary-material

- Meyer M, Colnat-Coulbois S, Frismand S, Vidailhet P, Llorca PM, Spitz E, et al. Parkinson's disease and bilateral subthalamic nuclei deep brain stimulation: beneficial effects of preoperative cognitive restructuration therapy on postoperative social adjustment. *World Neurosurg.* (2021) 145:282–9. doi: 10.1016/j.wneu.2020.09.128
- VanDusen KW, Li YJ, Cai V, Hall A, Hiles S, Thompson JW, et al. Cerebrospinal fluid proteome changes in older non-cardiac surgical patients with postoperative cognitive dysfunction. J Alzheimers Dis. (2021) 80:1281– 97. doi: 10.3233/JAD-201544
- Xiao QX, Liu Q, Deng R, Gao ZW, Zhang Y. Postoperative cognitive dysfunction in elderly patients undergoing hip arthroplasty. *Psychogeriatrics*. (2020) 20:501–9. doi: 10.1111/psyg.12516
- Nelissen R. Enhanced recovery after arthroplasty surgery. Acta Orthop. (2020) 91:226–7. doi: 10.1080/17453674.2020.1763565
- Yu BH, Xing Y, Zhang F. The therapeutic effect of electroacupuncture therapy for ischemic stroke. *Evid Based Complement Alternat Med.* (2020) 2020:6415083. doi: 10.1155/2020/6 415083
- Kim JH, Han JY, Park GC, Lee JS. Cognitive improvement effects of electroacupuncture combined with computer-based cognitive rehabilitation in patients with mild cognitive impairment: a randomized controlled trial. *Brain Sci.* (2020) 10:984–98. doi: 10.3390/brainsci10120984

- Li D, Li H, Liu H, Bao H, Zhu T, Tian J, et al. Impact of electroacupuncture stimulation on postoperative constipation for patients undergoing brain tumor surgery. J Neurosci Nurs. (2020) 52:257–62. doi: 10.1097/JNN.000000000000531
- Yang J, Huang L, Liu S, Wu W, Tian W, Zheng Z, et al. Effect of electroacupuncture on postoperative gastrointestinal recovery in patients undergoing thoracoscopic surgery: a feasibility study. *Med Sci Monit.* (2020) 26:e920648. doi: 10.12659/MSM.920648
- Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. *BMJ*. (2021) 372:n71. doi: 10.1136/bmj.n71
- Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Welch VA. Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (2021). Available online at: www.training.cochrane.org/handbook (accessed February 2021).
- Xu QG, Jiang L, He X, Chen DQ. Effect of electroacupuncture at "Siguan" points on postoperative cognitive function and serum HIF-1A in elderly patients with hip replacement. J Guizhou Med Univ. (2019) 44:1320– 4. doi: 10.19365/j.cnki.1000-2707.2019.11.015
- Zhao FY, Zhang ZY, Zhao YX, Yan HX, Hong YF, Xia XJ, et al. The effect of electroacupuncture preconditioning on cognitive impairments following knee replacement among elderly: a randomized controlled trial. *World J Acupunct Moxibustion*. (2018) 28:231–6. doi: 10.1016/j.wjam.2018.11.003
- Liu PR, Han ZX, Zhang Y, Gui M, Diao S. Effects of electroacupuncture on immune function, adrenal stress and cognitive function in elderly patients undergoing hip replacement. *Guid J Tradit Chin Med Pharm.* (2018) 24:95– 8. doi: 10.13862/j.cnki.cn43-1446/r.2018.08.030
- Liu PR, Peng S, Han ZX, Zhang Y, Diao S. Effect of electrocupuncture at "four close" points on cognitive function in elderly patients with hip replacement. J Tongji Univ Med Sci. (2017) 38:67–71. doi: 10.16118/j.1008-0392.06.014
- Tao T, Guo XW, Lv C, Zhang FF, Wang SP. Effect of electroacupuncture on cognitive dysfunction in elderly patients with insulin resistance after joint replacement. *Zhejiang J Tradit Chin Med.* (2017) 52:44– 5. doi: 10.13633/j.cnki.zjtcm.2017.01.033
- 22. Li XZ, Yu HF, Wang XM, Li JP, Zhang Y, Guo RY, et al. Effects of scalp acupuncture on serum NSE and S-100 β concentrations and postoperative cognitive function of elderly patients undergoing hip replacement. *Chin J Integr Tradit West Med.* (2016) 36:654–8. doi: 10.7661/CJIM.2016.06.0654
- Xie FL, Xu ZF, Xiong XH. Effect of mental tri-needle electro-acupuncture on postoperative cognitive function in elderly patients after hip joint replacement surgery. J Guangzhou Univ Tradit Chin Med. (2016) 33:813– 7. doi: 10.13359/j.cnki.gzxbtcm.2016.06.014
- Wang JT, Zhang YJ, Li JP, Li XZ, Liang F, Guo RY, et al. Effect of scalp acupuncture on postoperative cognitive function in elderly patients undergoing hip replacement. *Chin J Prim Med Pharm.* (2014) 21:2367– 9. doi: 10.3760/cma.j.issn.1008-6706.2014.15.061
- 25. Jiang HL, Chen LH, Wang DD, Zheng M, Cui SY. Effect of electroacupuncture preconditioning on postoperative cognitive dysfunction in elderly patients undergoing joint replacement. *Shanghai Med J.* (2014) 37:1017–9. https://d.wanfangdata.com.cn/periodical/ChlQZXJpb2RpY2FsQ0hJTmV3Uz IwMjExMTMwEg1zaHl4MjAxNDEyMDA 3GghiZmI5b3dqZA%3D%3D
- Zhang FF, Guo XW, Liu YL, Lv C. Clinical observation of electroacupuncture on postoperative cognitive dysfunction in elderly patients. *Chin J Tradit Chin Med Arch.* (2014) 32:370–1. doi: 10.13193/j.issn.1673-7717.2014.02.052
- Zhang FF, Guo XW, Xu YG, Liu YL, Lv C, Liu J. Effect of preoperative electroacupuncture on postoperative cognitive dysfunction in elderly patients with joint replacement. J Sci Tech Tradit Chin Med. (2012) 19:455– 7. doi: 10.3969/j.issn.1005-7972.2012.05.050
- Rasmussen LS. Postoperative cognitive dysfunction: incidence and prevention. Best Pract Res Clin Anaesthesiol. (2006) 20:315– 30. doi: 10.1016/j.bpa.2005.10.011
- Evered L, Scott DA, Silbert B, Maruff P. Postoperative cognitive dysfunction is independent of type of surgery and anesthetic. *Anesth Analg.* (2011) 112:1179– 85. doi: 10.1213/ANE.0b013e318215217e
- Brown EN, Purdon PL. The aging brain and anesthesia. Curr Opin Anaesthesiol. (2013) 26:414–9. doi: 10.1097/ACO.0b013e328362d183
- Halaszynski TM. Pain management in the elderly and cognitively impaired patient: the role of regional anesthesia and analgesia. *Curr Opin Anaesthesiol.* (2009) 22:594–9. doi: 10.1097/ACO.0b013e32833020dc

- Li WX, Luo RY, Chen C, Li X, Ao JS, Liu Y, et al. Effects of propofol, dexmedetomidine, and midazolam on postoperative cognitive dysfunction in elderly patients: a randomized controlled preliminary trial. *Chin Med J.* (2019) 132:437–45. doi: 10.1097/CM9.00000000000098
- 33. Li J, He J, Du Y, Cui J, Ma Y, Zhang X. Electroacupuncture improves cerebral blood flow and attenuates moderate ischemic injury via Angiotensin II its receptors-mediated mechanism in rats. *BMC Complement Altern Med.* (2014) 14:441. doi: 10.1186/1472-6882-14-441
- Torres-Rosas R, Yehia G, Pena G, Mishra P, Del RTM, Moreno-Eutimio MA, et al. Dopamine mediates vagal modulation of the immune system by electroacupuncture. *Nat Med.* (2014) 20:291–5. doi: 10.1038/nm.3479
- Cai M, Lee JH, Yang EJ. Electroacupuncture attenuates cognition impairment via anti-neuroinflammation in an Alzheimer's disease animal model. J Neuroinflammation. (2019) 16:264. doi: 10.1186/s12974-019-1665-3
- 36. Long M, Wang Z, Zheng D, Chen J, Tao W, Wang L, et al. Electroacupuncture pretreatment elicits neuroprotection against cerebral ischemia-reperfusion injury in rats associated with transient receptor potential vanilloid 1-mediated anti-oxidant stress and anti-inflammation. *Inflammation*. (2019) 42:1777– 87. doi: 10.1007/s10753-019-01040-y
- Manni L, Rocco ML, Barbaro PS, Guaragna M. Electroacupucture and nerve growth factor: potential clinical applications. *Arch Ital Biol.* (2011) 149:247– 55. doi: 10.4449/aib.v149i2.1365
- Han YG, Qin X, Zhang T, Lei M, Sun FY, Sun JJ, et al. Electroacupuncture prevents cognitive impairment induced by lipopolysaccharide via inhibition of oxidative stress and neuroinflammation. *Neurosci Lett.* (2018) 683:190– 5. doi: 10.1016/j.neulet.2018.06.003
- Liu S, Wang Z, Su Y, Ray R, Jing X, Wang Y, et al. Somatotopic organization and intensity dependence in driving distinct NPY-Expressing sympathetic pathways by electroacupuncture. *Neuron.* (2020) 108:436– 50. doi: 10.1016/j.neuron.2020.07.015
- Liu S, Wang Z, Su Y, Qi L, Yang W, Fu M, et al. A neuroanatomical basis for electroacupuncture to drive the vagal-adrenal axis. *Nature*. (2021) 598:641–5. doi: 10.1038/s41586-021-04001-4
- Li N, Hong SY, Li J, Wang GM, Liu Z, Liang Y. Effect of electroacupuncture pretreatment on hippocampal oxidative stress in aged mice with postoperative cognitive dysfunction. *Zhongguo Zhen Jiu.* (2021) 41:645–50. doi: 10.13703/j.0255-2930.20200415-0008
- 42. Lin EZ, Lin DH. Literature research on channels and acupoints of acupuncture therapy in treating. *Chin J Tradit Chin Med Pharm*. (2016) 31:4835–7. https://d.wanfangdata.com.cn/periodical/ChlQZXJpb2RpY2FsQ0hJTmV3U zIwMjExMTMwEg96Z3l5eGIyMDE2MTExMZAaCHFobHZ1NzE0
- 43. Zan FY, Wei JH, Wu RQ. Study on effects of baihui (GV 20) and yintang (EX-HN3) on cognitive function of rats after sevoflurane anesthesia and its mechanism. World J Tradit Chin Med. (2020) 15:738–42. https://d.wanfangdata.com.cn/periodical/ChlQZXJpb2RpY2FsQ0hJTmV3U zIwMjExMTMwEg5zanp5eTIwMjAwNTAxNBoIczRla3R5eHo%3D
- Zhang S, Gong P, Zhang J, Mao X, Zhao Y, Wang H, et al. Specific frequency electroacupuncture stimulation transiently enhances the permeability of the blood-Brain barrier and induces tight junction changes. *Front Neurosci.* (2020) 14:582324. doi: 10.3389/fnins.2020.582324

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Ou, Shen, Zhang, Chen, Zhang, Xu, Kong, Qi, Huang, Huang and Meng. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.